Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO4876904 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO4876904 1 | EXPERIMENTAL | Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin. |
| RO4876904 2 | EXPERIMENTAL | Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin. |
| RO4876904 3 | EXPERIMENTAL | Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin. |
| RO4876904 4 | EXPERIMENTAL | Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin. |
| Placebo | PLACEBO_COMPARATOR | Placebo po daily. Patients receiving metformin before the study will continue on the same dose of metformin. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo po daily. |
| RO4876904 | DRUG | Escalating doses, at a starting dose of 12.5mg po daily. |
Inclusion Criteria: * adult patients, 18-75 years of age; * type 2 diabetes diagnosed \>= 1 month before screening; * drug-naive, or pretreated with maximum tolerated dose (MTD) of metformin; * BMI 25-45kg/m2. Exclusion Criteria: * type 1 diabetes; * any anti-hyperglycemic medication other than m...
RO4876904 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is a dipeptidyl-peptidase IV (DPP-IV) inhibitor, a class of drugs that helps regulate blood sugar levels. The drug is currently in Phase 2 clinical development and is not yet approved for use.
RO4876904 targets the enzyme dipeptidyl-peptidase IV (DPP-IV). By inhibiting DPP-IV, the drug is designed to help manage blood glucose levels in patients with Type 2 Diabetes Mellitus. This mechanism is common in a class of diabetes medications known as gliptins.
RO4876904 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The drug is currently in Phase 2 clinical trials for Type 2 Diabetes Mellitus.
RO4876904 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of Type 2 Diabetes Mellitus, and its Phase 2 trial has been completed.
RO4876904 has one completed Phase 2 clinical trial registered as NCT00502710. This study, titled 'A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes,' enrolled 289 participants across multiple countries including the United States, Australia, and the United Kingdom. The trial was randomized, double-blind, and placebo-controlled.
RO4876904 is a specific DPP-IV inhibitor, meaning it belongs to the class of drugs that inhibit the enzyme dipeptidyl-peptidase IV. It is not the same as other DPP-IV inhibitors; it is a unique investigational compound developed by Roche. Its mechanism of action is shared with other drugs in this class.